Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dulamin
- Development stage
- Unknown
- Lead developer
- Schwabe
- Administration
- Oral
01
Overview
Dulamin is a proprietary botanical extract derived from the aerial parts of *Sideritis scardica* (commonly known as Greek Mountain Tea), developed by Dr. Willmar Schwabe GmbH & Co. KG. It is primarily investigated for its potential to enhance cognitive function, mood, and mental performance. The extract is characterized as a triple monoamine reuptake inhibitor, acting on the transporters for serotonin, norepinephrine, and dopamine, and has also demonstrated inhibitory activity against monoamine oxidase B (MAO-B). This pharmacological profile suggests potential therapeutic applications in conditions such as cognitive impairment, depression, and attention-deficit/hyperactivity disorder (ADHD). Clinical development has included Phase I stepwise ascending single-dose tolerability studies in healthy volunteers, evaluating doses from 150 mg to 2400 mg.
- Brand names
- Dulamin
- Other names
- Sideritis scardica extractGreek Mountain Tea extract
02
Targets
MAOB (Monoamine oxidase B)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on Dulamin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dulamin.